HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available

IRVINE & TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) –...

Click to view original post